1. Home
  2. MIRM vs PET Comparison

MIRM vs PET Comparison

Compare MIRM & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • PET
  • Stock Information
  • Founded
  • MIRM 2018
  • PET 2015
  • Country
  • MIRM United States
  • PET United States
  • Employees
  • MIRM N/A
  • PET N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • PET EDP Services
  • Sector
  • MIRM Health Care
  • PET Technology
  • Exchange
  • MIRM Nasdaq
  • PET Nasdaq
  • Market Cap
  • MIRM 1.9B
  • PET 8.4M
  • IPO Year
  • MIRM 2019
  • PET N/A
  • Fundamental
  • Price
  • MIRM $44.27
  • PET $0.15
  • Analyst Decision
  • MIRM Strong Buy
  • PET Strong Buy
  • Analyst Count
  • MIRM 10
  • PET 5
  • Target Price
  • MIRM $60.80
  • PET $4.90
  • AVG Volume (30 Days)
  • MIRM 425.9K
  • PET 11.3M
  • Earning Date
  • MIRM 05-07-2025
  • PET 05-12-2025
  • Dividend Yield
  • MIRM N/A
  • PET N/A
  • EPS Growth
  • MIRM N/A
  • PET N/A
  • EPS
  • MIRM N/A
  • PET N/A
  • Revenue
  • MIRM $379,251,000.00
  • PET $70,507,000.00
  • Revenue This Year
  • MIRM $29.51
  • PET $7.87
  • Revenue Next Year
  • MIRM $20.27
  • PET $122.23
  • P/E Ratio
  • MIRM N/A
  • PET N/A
  • Revenue Growth
  • MIRM 69.31
  • PET N/A
  • 52 Week Low
  • MIRM $23.83
  • PET $0.08
  • 52 Week High
  • MIRM $54.23
  • PET $2.47
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.45
  • PET 49.37
  • Support Level
  • MIRM $40.00
  • PET $0.14
  • Resistance Level
  • MIRM $47.43
  • PET $0.16
  • Average True Range (ATR)
  • MIRM 2.07
  • PET 0.03
  • MACD
  • MIRM 0.54
  • PET 0.01
  • Stochastic Oscillator
  • MIRM 65.27
  • PET 54.95

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About PET Wag! Group Co.

Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools and pet wellness plans.

Share on Social Networks: